Virios Therapeutics, Inc.
VIRI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,521,342 | $2,569,943 | $2,436,998 | $3,529,935 |
| G&A Expenses | $1,287,783 | $1,353,172 | $1,992,928 | $8,693,791 |
| SG&A Expenses | $1,287,783 | $1,353,172 | $1,992,928 | $8,693,791 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,809,125 | $3,923,115 | $4,429,926 | $12,223,726 |
| Operating Income | -$15,809,125 | -$3,923,115 | -$4,429,926 | -$12,223,726 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $63,073 | $115,911 | -$6,304,484 | -$123,057 |
| Pre-Tax Income | -$15,746,052 | -$3,807,204 | -$10,734,410 | -$12,346,783 |
| Tax Expense | -$1,436 | $149 | $190,542 | $1,775 |
| Net Income | -$15,744,616 | -$3,807,353 | -$12,181,614 | -$12,859,207 |
| % Margin | – | – | – | – |
| EPS | -8.2 | -1.99 | -8.45 | -12.35 |
| % Growth | -312.1% | 76.4% | 31.6% | – |
| EPS Diluted | -8.2 | -1.99 | -8.45 | -12.35 |
| Weighted Avg Shares Out | 1,919,433 | 1,911,128 | 1,441,535 | 1,027,788 |
| Weighted Avg Shares Out Dil | 1,919,433 | 1,911,128 | 1,441,535 | 1,027,788 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $78 |
| Interest Expense | $0 | $111,379 | $147,090 | $92,232 |
| Depreciation & Amortization | $2,063 | $0 | $0 | -$2,452 |
| EBITDA | -$15,743,989 | -$3,923,115 | -$4,429,926 | -$12,223,900 |
| % Margin | – | – | – | – |